Abstract
Macromolecular drugs (e.g., proteins and nucleic acids) are highly environmentally liable and unstable, and their administration is strictly limited to injection. Moreover, a vast majority of macromolecules are cell membrane- impermeable, and it is a critical issue to enhance the cellular uptake efficiency for improving the treatment outcomes. Cell-penetrating peptide (CPP)-assisted strategy is promising for effective macromolecular delivery. As a case in point, CPP-mediated protein delivery has been considered as a revolutionary breakthrough. With aid of CPP, virtually all pro- teins can become cell-permeable. Generally, CPP-protein delivery works in a covalent delivery pattern, by which CPP and its cargo are linked via covalent bond. Recently, noncovalent delivery has also attracted attention for its potential application for protein delivery. In the presented work, the noncovalent pattern was demonstrated for its feasibi lity in percutaneous and nose-to-brain delivery with TAT/GFP as model drug, in comparison with the covalent method. Noncovalent CPP/protein delivery and its noninvasive application may provide a facile method for protein therapy.
Keywords: Cell-penetrating peptide, noncovalent, nose-to-brain delivery, percutaneous delivery, protein delivery, TAT.
Protein & Peptide Letters
Title:CPP-mediated Protein Delivery in a Noncovalent Form: Proof-of-Concept for Percutaneous and Intranasal Delivery
Volume: 21 Issue: 11
Author(s): Zhao Wang, Yingzhi Chen, Ergang Liu, Junbo Gong, Meong Cheol Shin and Yongzhuo Huang
Affiliation:
Keywords: Cell-penetrating peptide, noncovalent, nose-to-brain delivery, percutaneous delivery, protein delivery, TAT.
Abstract: Macromolecular drugs (e.g., proteins and nucleic acids) are highly environmentally liable and unstable, and their administration is strictly limited to injection. Moreover, a vast majority of macromolecules are cell membrane- impermeable, and it is a critical issue to enhance the cellular uptake efficiency for improving the treatment outcomes. Cell-penetrating peptide (CPP)-assisted strategy is promising for effective macromolecular delivery. As a case in point, CPP-mediated protein delivery has been considered as a revolutionary breakthrough. With aid of CPP, virtually all pro- teins can become cell-permeable. Generally, CPP-protein delivery works in a covalent delivery pattern, by which CPP and its cargo are linked via covalent bond. Recently, noncovalent delivery has also attracted attention for its potential application for protein delivery. In the presented work, the noncovalent pattern was demonstrated for its feasibi lity in percutaneous and nose-to-brain delivery with TAT/GFP as model drug, in comparison with the covalent method. Noncovalent CPP/protein delivery and its noninvasive application may provide a facile method for protein therapy.
Export Options
About this article
Cite this article as:
Wang Zhao, Chen Yingzhi, Liu Ergang, Gong Junbo, Shin Cheol Meong and Huang Yongzhuo, CPP-mediated Protein Delivery in a Noncovalent Form: Proof-of-Concept for Percutaneous and Intranasal Delivery , Protein & Peptide Letters 2014; 21 (11) . https://dx.doi.org/10.2174/0929866521666140807121903
DOI https://dx.doi.org/10.2174/0929866521666140807121903 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cognition and Emotions in Recurrent Depressive Disorders - The Role of Inflammation and the Kynurenine Pathway
Current Pharmaceutical Design Rationale Design, Synthesis, Cytotoxicity Evaluation, and Molecular Docking Studies of 1,3,4-oxadiazole Analogues
Anti-Cancer Agents in Medicinal Chemistry Treatment of Interstitial Lung Disease Associated with Polymyositis- Dermatomyositis: An Update
Current Respiratory Medicine Reviews Ligand-Based Peptide Design and Combinatorial Peptide Libraries to Target G Protein-Coupled Receptors
Current Pharmaceutical Design <i>In Silico</i> and <i>in Vitro</i> Evaluation of Deamidation Effects on the Stability of the Fusion Toxin DAB<sub>389</sub>IL-2
Current Proteomics Genetic and Pharmacogenetic Aspects of Alcohol-Dependence
Current Pharmacogenomics Gender Differences in Metabolic Syndrome – A Key Research Issue
Endocrine, Metabolic & Immune Disorders - Drug Targets Erratum to Phytochemicals for the management of melanoma
Mini-Reviews in Medicinal Chemistry Exosomal miR-1298 and lncRNA-RP11-583F2.2 Expression in Hepatocellular Carcinoma
Current Genomics Glycolipids as Immune Modulatory Tools
Mini-Reviews in Medicinal Chemistry Traditional Uses, Phytochemistry, Pharmacology and Anticancer Activity of Açaí (Euterpe oleracea Mart): A Narrative Review
Current Traditional Medicine The Potential Use of Hormone-Based Therapeutics for the Treatment of Alzheimers Disease
Current Alzheimer Research New Insights into Neoangiogenesis and Breast Cancer Development and Progression
Current Angiogenesis (Discontinued) Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology 6-Bromo-2,3-Dioxoindolin Phenylacetamide Derivatives: Synthesis, Potent CDC25B, PTP1B Inhibitors and Anticancer Activity
Letters in Drug Design & Discovery Anti-tumor Therapeutic Molecules that Target the Programmed Cell Death Machinery
Mini-Reviews in Medicinal Chemistry Radiation Protection of the Child from Diagnostic Imaging
Current Pediatric Reviews Pharmacological Modulation of Genome and Proteome Alterations in Mice Treated with the Endocrine Disruptor Bisphenol A
Current Cancer Drug Targets Cartilage Oligomeric Matrix Protein: Matricellular and Matricrine Signaling in Cardiovascular Homeostasis and Disease
Current Vascular Pharmacology Sorafenib (BAY 43-9006): Review of Clinical Development
Current Clinical Pharmacology